Verismo Therapeutics Treats First Follicular Lymphoma Patient in CELESTIAL-301 Trial, Strengthening Collaboration with IFLI

Excerpt from the Press Release:

PHILADELPHIA, Oct. 2, 2025 /PRNewswire/ — Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has treated the first patient with follicular lymphoma (FL) in its CELESTIAL-301 Phase 1 clinical trial of SynKIR™-310. This milestone reflects Verismo’s commitment to addressing the urgent unmet medical need for patients with FL and further strengthens the company’s collaboration with the Institute for Follicular Lymphoma Innovation (IFLI).

CELESTIAL-301 is a multicenter Phase 1 trial (NCT06544265) evaluating the safety, tolerability, and preliminary efficacy of SynKIR™-310 in patients with relapsed/refractory B cell non-Hodgkin lymphomas (B-NHL), including FL. The study is enrolling both patients who have relapsed after prior CAR T therapy as well as those who never received CAR T treatment.

SynKIR™-310 combines Verismo’s proprietary KIR-CAR platform with a new CD19 binder, which was developed by the University of Pennsylvania (Penn) under a sponsored research agreement between Penn and Verismo and exclusively licensed to Verismo, to target malignant B cells. Preclinical studies indicated that the KIR-CAR technology may extend T cell persistence, offering the potential to reduce relapse rates. The trial design includes 2 cohorts with dose escalation and an expansion cohort at the recommended Phase 2 dose.

Click the button below to read the entire Press Release:

Continue Reading The Press Release